QIAGEN - Marktführer im Milliardenmarkt molekularer Diagnostik (Seite 122)

[VaJo]

Qiagen verhält sich wie ein mittelmäßiger Fonds. Absolut nervig.
Die Zahlen stimmen doch es passiert nix

[VaJo]

Wenns so weiter läuft sehen wir bei Qiagen Ende 2012 2 Milliarden Umsatz. Einfach herrlich!

[VaJo]

81% Plus im Nettoergebnis. Der Gewinn hat ebenfalls klasse zugelegt. Und das trotz der ganzen Zukäufe. Und Qiagen setzt noch einen oben drauf und kauft gleich nochmal dazu. Diese 90 Millionen fallen jetzt gar nicht mehr auf

[VaJo]

Die Erwartungen wurden weit übertroffen. Jetzt wird es Zeit das endlich mal der Kurs die Entwicklung reflektiert.

[justfollowme]

QIAGEN to Acquire SABiosciences
Press Release
Source: Qiagen N.V.
On 4:26 pm EST, Monday November 9, 2009
Companies:Qiagen Nv
KJ VENLO, GERMANY--(Marketwire - 11/09/09) -


Transaction adds to QIAGEN's content engine for development of future diagnostics and boosts the Company's presence in pharma discovery and validation

VENLO, The Netherlands, November 9, 2009 - QIAGEN N.V. (NASDAQ:QGEN - News) (Frankfurt, Prime Standard: QIA) today announced that it has signed a definite agreement to acquire SABiosciences Corporation, a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels. SABiosciences is based in Frederick, Maryland (USA), and employs a staff of around 100. The transaction is valued at US$90 million in cash (subject to customary purchase price adjustments) and is expected to close in late December 2009, following approval of SABiosciences' stockholders and the expiration of the statutory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

SABiosciences holds a leading position in the design and commercialization of disease- and pathway-focused real-time PCR-based assay panels ("PCR Arrays"), which are widely utilized in biomedical research and in the development of future drugs and diagnostics. The company's primary product family includes more than 100 real-time PCR assay panels designed for high-performance analysis of DNA, RNA, epigenetic and microRNA targets in biological pathways associated both with specific diseases such as cancer, diabetes, immune and cardiovascular disorders, as well as with pathways such as apoptosis (programmed cell death), signal transduction and toxicology.

Solutions focusing on the analysis of molecular interactions in pathways - a series of actions among molecules in a cell - open up a new dimension for gene analysis. Conventional assay products are usually designed for the study of a single gene's expression and not offered in complete panels covering all genes of interest associated with a specific disease or pathway. SABiosciences, in contrast, is a pioneer in the design of preformatted PCR assay panels and focuses on the biology of entire pathways and interaction of all genes involved in a specific disease. In a single experiment users can therefore learn how gene activity in their samples correlates with the state of a disease of their particular interest. As such, SABiosciences' expertise and unique offering lie in the biomedical and bioinformatics know-how required to design and format such assay panels. Its approach allows biomedical researchers and pharmaceutical companies to facilitate and accelerate the discovery and validation of biomarkers.

The discovery and validation of biomarkers is also of key interest in the development of diagnostics. By supplying disease- and pathway-focused panels to biomedical and pharma activities in discovery and preclinical research, QIAGEN can contribute to the discovery and validation engines of biomedical and pharma institutions. This can prompt collaborations around these engines to create fast-track approvals to new diagnostic content for prevention, profiling (as spin-offs of pharmaceutical research), and personalized healthcare (as an integral interest of the pharmaceutical companies). The transaction is therefore also highly synergistic with QIAGEN's recent acquisition of DxS Ltd which has put the Company in a leading position in the emerging field of personalized healthcare.

"SABiosciences is a leader in design and commercialization of disease- and pathway-based PCR assay panels", said Peer Schatz, CEO of QIAGEN. "These assay panels are designed for use with and leveraged by QIAGEN's sample and assay technologies and can be run on QIAGEN instruments. Subject to final closing, the transaction can create great value for both our strategy in pharma and our strategy in diagnostics. The addition of SABiosciences will boost our biological content engine significantly by adding to our position as a premium partner for the pharmaceutical industry and to the use of this position to yield diagnostic content for prevention, profiling, and, most significantly, personalized healthcare."

"We are very delighted with this merger", said Li Shen, President of SABiosciences. "The combination of SABiosciences' strong content development and bioinformatics capability with QIAGEN's leadership in molecular biology and its global footprint allow us to take our proven PCR Array technology to the next level. Together with QIAGEN we can roll out this technology internationally and bundle it with one of the industry's most reputed product portfolios, thereby providing even more value to our customers."

SABiosciences' operations are located in the immediate vicinity of QIAGEN's North American headquarters based in Germantown and Gaithersburg, Maryland. This proximity is expected to contribute to a rapid and smooth integration of SABiosciences into QIAGEN operations. Subject to the closing of the transaction, QIAGEN intends to further expand the segment of disease- and pathway-focused assay panels. QIAGEN also intends to establish SABiosciences' Frederick site as a Center of Excellence in biological content development and - due to the high level of synergies - to further grow the location in the near future.

Highlights of the acquisition agreement signed:


�
* Subject to SABiosciences' stockholder approval and the expiration
of the statutory waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976.
* Consideration of US$90 million in cash (subject to customary
purchase price adjustment).
* Expected to add revenues of approximately US$24 million in sales
for 2010. The growth rate on these $24 million in revenues is
expected above QIAGEN's average growth rate.
* Expected one-time charges of approximately US$0.02 in earnings
per share (EPS) in the last quarter of 2009 which primarily
related to costs and expenses incurred in connection with the
acquisition such as advisory fees as well as the write-off of
certain assets.
* On an adjusted basis excluding one-time charges, integration and
restructuring costs, and amortization of acquisition related
intangible assets, the acquisition is expected to be neutral to
EPS in 2010 and to significantly accretive to adjusted EPS in
2011.


About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,300 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

About SABiosciences:

SABiosciences Corporation, a privately held biotechnology company founded in 1998, envisions a new and systematic approach to biological research in the post-genomic era. In recognition of its strong performance, SABiosciences has received many awards including Inc. 5000 Fastest Growing Companies (2007 and 2008), The Scientist Magazine's 2009 Top 30 Best Places to Work Award. For more information about SABiosciences, visit www.SABiosciences.com

SAFE HARBOR STATEMENT

Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing, molecular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.




�
Contacts:


Investor Relations: Public Relations: Dr. Solveigh M�hler Dr. Thomas Theuringer Director Investor Relations Associate Director Public QIAGEN N.V. Relations [phone] QIAGEN GmbH e-mail: [phone] [e-mail] e-mail: [e-mail] Albert F. Fleury Investor Relations North America QIAGEN N.V. [phone] e-mail: [e-mail]


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright � Hugin AS 2009. All rights reserved.

[quepos]

Wie erwartet gut:



UPDATE 1-Qiagen beats estimates, tweaks outlook on test sales
Mon Nov 9, 2009 4:07pm EST Email | Print | Share| Reprints | Single Page[-] Text [+]
Market News
Stocks jump on increased risk appetite | Video
Oil jumps 3 percent on Ida, equities | Video
Gold hits record above $1,110/oz as dollar slides
More Business & Investing News... Featured Broker sponsored link
* Sees FY adj EPS of $0.88-$0.90 vs $0.86-$0.90 previously

* Q3 adj net income $53.5 mln vs Rtrs poll avg of $49 mln

* Higher demand for tests for HPV, tumour mutations (Adds details, background)

FRANKFURT, Nov 9 (Reuters) - Germany's Qiagen (QGEN.DE) (QGEN.O) tweaked its full-year earnings outlook and posted better-than-expected quarterly results as more doctors used its testing kits for the cervical cancer virus.

The genetic-tests specialist said on Monday that 2009 adjusted diluted earnings per share would be between $0.88 and $0.90, lifting the lower limit from $0.86 previously, adding that the target was based on Jan. 31 foreign exchange rates.

Healthcare reform in the United States, the group's biggest market, looked set to further boost demand for tests to identify the human papilloma virus (HPV), which can cause cervical cancer, Chief Executive Peer Schatz said.

"This would give us a bigger market potential. HPV tests are part of the standard healthcare coverage in the U.S.," the CEO told Reuters on Monday.

Qiagen -- listed in the Netherlands but with its main operations in Germany -- derives more than a quarter of total sales from genetic HPV tests.

Third-quarter net profit, excluding one-off items related to acquisitions, rose 26 percent to $53.5 million, better than the $49 million average estimate in a Reuters poll of 10 analysts.

Sales rose 15 percent excluding the effect of currency swings and acquisitions, also topping market estimates.

Qiagen also benefited from higher demand for tests that help identify those bowel-cancer patients who are most likely to benefit from Merck KGaA's (MRCG.DE) anti-tumor drug Erbitux or from Amgen's (AMGN.O) Vectibix.

In the United States, Qiagen is the exclusive supplier of tests needed before Vectibix and Erbitux can be used while in Europe it has an 80 percent market share, the CEO said.

Personalised medicine, or screening patients' genetic profile to find the best therapy, accounts for about 5 percent of group sales, Schatz said.

"That's just the tip of the iceberg. We have five to six tests in the regulatory approval process in the U.S. with an annual peak sales potential of $50-$100 million each," he added.

Qiagen in September shored up its cancer diagnostics business by acquiring British peer DxS Ltd for up to $130 million.

Schatz on Monday repeated that more deals were in the offing, adding that such takeovers would complement Qiagen's main businesses and would not be transformational.

Qiagen's shares trade at 24 times estimated earnings over the next 12 months, above the multiple of 19 for the global life sciences tools and services industry, according to Thomson Reuters StarMine, which weights estimates according to analysts' track record. (Reporting by Ludwig Burger)




© Thomson Reuters 2009 All rights reserved

[VaJo]

MILLIARDE WIR KOMMEN

QIAGENs Ergebnis für Q3 2009 (in Millionen US$, ausgenommen
Gewinn je Aktie)
Q3 2009 Q3 2008 Wachstum

Umsatzerlöse 259,7 230,8 13%
Umsatzerlöse unter konstanten
Wechselkursen 268,7 230,8 16%
Operativer Gewinn, bereinigt 81,8 66,8 22%
Gewinn, bereinigt 53,5 42,4 26%

[VaJo]

FANTASTICO

QIAGEN ist wieder auf Einkaufstour - hehe!

[justfollowme]

Die müssen mindestens stichprobenartig Tests führen, um zu wissen, womit man zutun hat. Ansonsten tappt man im dunkeln!
Mal gucken wie die Zahlen heute Abend werden.

[VaJo]

Es werden von Seiten der Staaten nur noch in begründeten Ausnahmefällen H1N1 Tests durchgeführt. Die Kosten für die Tests sind explodiert. Laut meinem Hausarzt muss ich wenn ich mit Grippesymptomen wissen möchte ob es H1N1 ist den Test selbst bezahlen (90 EUR). Er sagte das macht auch Sinn solange die Symptome nur wie bei einer normalen Grippe verlaufen.